Business Context and Reporting Period
Company: DuPont de Nemours, Inc. (DD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: DuPont is a leading provider of advanced solutions in healthcare, water, construction, and industrial markets. The company operates through two reportable segments: Healthcare & Water Technologies and Diversified Industrials. The 2025 fiscal year was defined by significant portfolio transformations, including the separation of the Electronics Business into Qnity Electronics, Inc. (Qnity) on November 1, 2025, and the agreement to divest the Aramids Business.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Sales (Continuing Ops) | $6,849 | $6,719 | $6,614 |
| Income from Continuing Ops (Pre-tax) | $200 | $117 | $(279) |
| Net Income (Loss) from Continuing Ops | $98 | $(96) | $(62) |
| Net (Loss) Income (Total) | $(738) | $738 | $462 |
| Operating Cash Flow (Continuing Ops) | $560 | $765 | $845 |
| Total Debt | $3,194 | $7,171 | N/A |
| Cash and Cash Equivalents | $715 | $1,792 | N/A |
| Effective Tax Rate (Continuing Ops) | 51.0% | 182.1% | 77.7% |
Note: Total Net Loss for 2025 includes a significant loss from discontinued operations ($836 million), primarily driven by the Aramids Divestiture impairment and classification adjustments.
Material Changes vs. Prior Period
- Portfolio Restructuring: The company completed the separation of its Electronics Business (Qnity) on November 1, 2025, receiving a $4.1 billion cash distribution. This business is now reported as discontinued operations. The Aramids Business is also classified as discontinued operations pending its sale to Arclin, expected to close in Q1 2026.
- Revenue Growth: Net sales from continuing operations increased 2% to $6.8 billion, driven by a 7% volume increase in Healthcare & Water Technologies, partially offset by a 1% volume decline in Diversified Industrials.
- Debt Reduction: Total debt decreased significantly from $7.2 billion in 2024 to $3.2 billion in 2025. This reduction was achieved through the repayment of $1.85 billion in notes maturing in 2025 and debt exchanges/redemptions funded by the Qnity cash distribution.
- Segment Realignment: Effective Q4 2025, the company realigned its reporting structure into two segments: Healthcare & Water Technologies and Diversified Industrials.
- Impairments: A $768 million goodwill impairment charge related to the Aramids Business was recorded in discontinued operations. Additionally, a $437 million loss was recorded for the classification of the Aramids Business as held for sale.
Guidance, Outlook, and Risks
2026 Outlook
- Healthcare: Expected continued growth driven by medical packaging and devices.
- Water: Expected growth driven by reverse osmosis and ion exchange demand.
- Building Technologies: Expected to be flat following market declines, with stabilization in U.S. construction markets.
- Industrial Technologies: Expected low-single digit growth driven by aerospace strength and demand recovery.
- Capital Expenditures: Expected to be approximately $320 million for 2026.
Key Risks and Contingencies
- PFAS Liabilities: Significant exposure to PFAS-related litigation and remediation costs. The company is part of a cost-sharing MOU with Chemours and Corteva. A proposed Judicial Consent Order with the State of New Jersey (NJ Settlement) was agreed upon in August 2025, resulting in a $186 million liability accrual (pre-tax charge of $177 million recorded in 2025).
- Transaction Risks: Risks associated with the tax-free treatment of the Qnity Distribution and the successful closing of the Aramids Divestiture.
- Geopolitical and Trade: Exposure to trade disputes, tariffs, and export controls, particularly regarding China (approx. 10% of consolidated net sales).
- Cybersecurity: Ongoing risks of cyber-attacks, though no material impact on financial condition was reported for 2025.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the magnitude of the $836 million loss from discontinued operations and its specific drivers (Aramids impairment vs. Electronics separation costs).
- PFAS Liability Exposure: Review the status of the New Jersey Settlement and the potential for additional costs under the MOU cost-sharing arrangement beyond the $186 million accrued.
- Debt Structure: Confirm the terms of the remaining debt portfolio ($3.2 billion) and the impact of the debt exchange/redemptions on future interest expenses.
- Qnity Separation Tax Status: Monitor for any IRS challenges to the tax-free treatment of the Qnity Distribution, which could result in significant tax liabilities.
- Aramids Closing: Track the progress of the Aramids Divestiture closing in Q1 2026 and any adjustments to the $1.8 billion gross consideration.